Biosimilars remain a hot topic in rheumatology, and some physicians are cautious about
their application in the real world. With many products coming to market and a wealth of …

Objective Cost per quality-adjusted life year data are required for reimbursement decisions
in many Central and Eastern European (CEE) countries. EQ-5D is by far the most commonly …

This paper describes and discusses the development and use of health technology
assessment (HTA) in five Central and Eastern European countries (CEE): Poland, the Czech …

Objectives The wording of the Hungarian EQ-5D-3L and EQ-5D-5L descriptive systems
differ a great deal. This study aimed to (1) develop EQ-5D-3L and EQ-5D-5L value sets for …

Background There is a growing interest in policy making for using utility measures and
identifying algorithms to convert disease-specific measures into utilities. Objectives To analyse …

Objectives: To estimate the budget impact of the introduction of biosimilar infliximab for the
treatment of Crohn’s disease (CD) in Bulgaria, the Czech Republic, Hungary, Poland, …

Introduction New biosimilars of monoclonal antibodies are anticipated to bring significant
cost savings and increase access to treatment. The rituximab biosimilar CT-P10 has recently …

Biological drugs opened up new horizons in the management of inflammatory bowel diseases
(IBD). This study focuses on access to biological therapy in IBD patients across 9 selected …

Background Sensors and digital devices have revolutionized the measurement, collection,
and storage of behavioral and physiological data, leading to the new term digital biomarkers. …

Background and aims To assess work disability (WD) rates in an inflammatory bowel disease
(IBD) cohort involving patients with Crohn’s disease (CD) or ulcerative colitis (UC) cohort …